Research by Pahwa et al. demonstrated that HSP90 inhibition, using the specific inhibitor SNX2112, elicits potent anti-tumor effects in PRCC models, evidenced by the induction of apoptosis, G2/M cell cycle arrest, and suppression of oncogenic pathways such as PI3K/AKT and MEK/ERK1/2. The gene discussed is HSP90AB1; the disease is neoplasm.